Seres Therapeutics Concludes Enrollment In Cohort 2 Of Phase 1B Trial Of SER-155 In Allogeneic Hematopoietic Stem Cell Transplant Patients; Clinical Data Readout Expected End Of Q3 2024
Seres Therapeutics 完成了針對異基因造血幹細胞移植患者的 SER-155 1B 期試驗 2 隊列的入組;臨床數據預計將於 2024 年第三季度末公佈